News

The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with chronic obstructive pulmonary disease (COPD) associated with

Mr Lemaitre has led Medtronic’s corporate strategic planning and corporate development functions since 2006 and also served as a senior member of Medtronic’s policy, management, strategy, and investment

Ulf Wiinberg will be leaving the US pharmaceutical company Wyeth, where he has been responsible for two areas – Strategic oversight of Wyeth’s biopharma activities and as president

The supplemental new drug application (sNDA) submission is based on results from two pivotal efficacy and safety trials with Symbicort pressurised meter dose inhaler. Both studies were randomized,

Under this agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other activities (clinical, non-clinical, etc). Foamix will receive staged payments

The program, funded in large part by the National Institute of Allergy and Infectious Diseases (NIAID), is intended to supply efficacy data for RiVax in vaccinated rhesus monkeys

The four-arm randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis (RMS) over 36 weeks of treatment.

The test has also been cleared for US marketing by the FDA under the 510(k) procedure. The forthcoming global launch of this new test will now incorporate the

This renewal marks the second renewal of the license since Deanxit was first registered with the SFDA in 1999. The license grants H Lundbeck the manufacturer of Deanxit,